Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, diagnosed with Alzheimer's disease in Charlotte's own laboratory 👉 https://lnkd.in/eV363SQN Hear them talk about the difficult acceptance of the diagnosis and how to live with the disease. And hear about partnering in the search for earlier and better diagnostic testing solutions. 🔬 👩🔬 👋 ADx NeuroSciences Ann De Vos Amsterdam UMC Amsterdam UMC - Alzheimer Center Amsterdam #FNCE #alzheimersdisease
概要
Fujirebio is is a global leader in the field of high-quality in vitro diagnostics (IVD) and an R&D-driven company constantly developing new technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care. Our global teams located in Japan, Asia, Europe and the US focus on delivering products with the highest quality standards to our customers and partners. We value partnerships with other leading companies in the industry, sharing knowledge, capabilities, and critical materials in order to supply, develop or manufacture diagnostic solutions on a wide variety of platforms. Through this business model, we ensure that the potentially life-changing diagnostic markers meet the largest global need in the shortest possible time. Fujirebio has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions. Founded in 1950 in Tokyo, Japan, Fujirebio has over the years concluded a number of successful acquisitions of best-in-class IVD companies. Examples include Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010. Today, Fujirebio’s global presence includes offices in the United States, Latin America, Europe and Asia as well as a vast international distribution network. Fujirebio is today a consolidated subsidiary of H.U. Group Holdings, Inc. (listed on the Tokyo Stock Exchange – TYO: 4544) and employs more than 1,200 people in Asia, Europe and America.
- ウェブサイト
-
http://www.fujirebio.com
Fujirebio Europeの外部リンク
- 業種
- バイオテクノロジー研究
- 会社規模
- 社員 1,001 - 5,000名
- 本社
- Gent
- 種類
- 上場企業
- 創立
- 1950
- 専門分野
- IVD、in vitro diagnostics、immunoassays、molecular diagnostics、multiparameter testing、strip-based diagnostics、infectious diseases、tumour markers、genetic testing、thyroid、fertility、tissue typing、neurodegeneration、bone testing、alzheimer's disease、virology、line immunoassays、CDMO、OEM、parkinson's disease、multiple sclerosis、HPV、DNA methylation、molecular biology
場所
Fujirebio Europeの社員
アップデート
-
Fujirebio Europeさんが再投稿しました
📰 Tokyo, Japan, Malvern PA, and Gent, Belgium, July 26, 2024 – H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio announced today the availability of the Lumipulse® G GFAP assay for the fully automated, random-access LUMIPULSE® G immunoassay systems. The Research Use Only (RUO) assay is now available in the United States and will be available in Japan, Europe and other regions* as of September this year. The Chemiluminescent Enzyme Immunoassay (CLEIA) test allows for the quantitative measurement of glial fibrillary acidic protein (GFAP) in human plasma and serum in just 35 minutes. Learn more 👉 https://bit.ly/3LwJ5SS
-
-
Fujirebio Europeさんが再投稿しました
We will be at ADLM 2024 in Chicago! Visit us at our booth, 1032. Please contact us for more information on our contract, development and manufacturing capabilities. Learn more👉 https://bit.ly/3zHdgEr
-
-
Fujirebio Europeさんが再投稿しました
📰 San Diego, CA, Tokyo, Japan and Malvern, PA -- (BUSINESS WIRE), July 12th, 2024 – Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced earlier this week the attainment of the first milestone in a strategic partnership to advance the development of biomarkers for Alzheimer’s disease (AD) and other neurodegenerative conditions. This milestone marks a key achievement which provides Fujirebio access to clinical samples and data collected as part of the ongoing Phase 3 Alzheimer’s disease study, POLARIS-AD. Learn more 👉 https://bit.ly/4f0cUsz
-
-
Fujirebio Europeさんが再投稿しました
We're #hiring a new Senior Research Associate in Sunnyvale, California. Apply today or share this post with your network.
-
Fujirebio Europeさんが再投稿しました
We will be at AAIC 2024 in Philadelphia! Schedule a meeting with us or stop by our booth to learn about our high-quality assays for assessing neurodegenerative disorders. 👉 https://bit.ly/4bxAqdu or email us at [email protected]. We look forward to meeting with you. #AAIC24
-
-
Fujirebio Europeさんが再投稿しました
🔊 We are ready for a new adventure🔊 🧬We have installed our first fully automated, traceable and userfriendly system that combines the extraction and preparation of the Masmec S.p.A. - Biomed division OMNIA LH 75 Pro with the real time detection and interpretation of the BMS Mic qPCR🧬 Our Giulia Alfedi completed the installation and training at our first customer who will use our HPV unique solution: Self-screen B.V. HPV screening (HPV Risk Assay), HPV genotyping (INNOLiPA HPV genotyping Extra II) and methylation analysis (Precursor-M ). 🔬 The Fujirebio Europe Art of Accuracy in everyday life and at the service of precision medicine! Rikkert Maertens Rebecca Millecamps Christian Lindknud, MSc Michelle Meijer Vincenzo Costantino MICHELE MARFORI Maria Assunta Melone Guido Marelli Iosto Doneddu
-
-
Fujirebio Europeさんが再投稿しました
Discover our interview to our collaborators ADx NeuroSciences and Fujirebio Europe within the NEuroBioStand project. Thanks to Eugeen Vanmechelen and Nathalie Le Bastard (article in French). EURAMET - The European Association of National Metrology Institutes #EUpartnership #metrology LNE
-
🌐 BE - The Fujirebio Neuro Center of Excellence was proudly featured in the Belgian newspaper De Morgen in this interview with our own Dr. Nathalie Le Bastard and Manu Vandijck; learn about the past, present and future of this exciting place... and the current state of neuro testing in general 👉 https://lnkd.in/enzJM_QV 👏
-
Are you our new IT Business Analyst? 🤗 We are strengthening our IT team in Ghent, Belgium 👉 https://lnkd.in/gdFN7ui5 In taking up this job you will analyse, redesign and improve business processes, and you will manage the full life cycle of corporate business applications and/or Business Intelligence systems. 💪 #joinus #teamfujirebio
-